Skip to main content

8110 Gatehouse Road, Falls Church, VA 22042

Arthur A. Winer, MD

A member of Inova Medical Group
The doctors of Inova Medical Group are Inova’s premier primary care and specialty physicians, offering top-notch medical expertise, full access to Inova facilities, and the convenience of integrated electronic medical records.
Arthur Winer, MD

Specialty

Board-certified specialties granted by an ABMS Member Board. Learn more about board certification.
Medical Oncology (Eligible), Hematology (Eligible), Internal Medicine

Clinical Interest

Areas of special interest identified by the physician or additional training completed.
Colorectal Cancer, Esophageal Cancer, Gastrointestinal (GI) Cancer, Liver Cancer, Pancreatic Cancer

Years of Experience

7

Gender

Male

Languages

English
Request Profile Update
Translate

About Arthur Winer, MD

Dr. Arthur Winer is a specialty care physician board certified in internal medicine and board eligible in hematology/oncology. He joined Inova Health System in 2020 and has been practicing since 2013.

Prior to joining Inova, Dr. Winer attended New York University School of Medicine where he graduated from medical school and completed his training in internal medicine. He also completed an additional year as an internal medicine chief resident. Most recently, he trained as a hematology/oncology fellow at Temple University Hospital/Fox Chase Cancer Center in Philadelphia, PA.

Memberships/Accreditations

  • American Society of Clinical Oncology
  • National Comprehensive Cancer Network
  • Pennsylvania Medical Society

Publications

Winer A, Denlinger C, Vijayvergia N, Cohen SJ, Astaturov I, Dotan E, Gallant JN, Wang E, Kunkel M, Lim B, Harvey H, Sivik J, Korzekwa K, Ruth K, White K, Cooper H, Ross E, Zhou L, El-Diery W. First-in-Human Phase Ib Trial of Quinacrine plus Capecitabine in Patients with Refractory Metastatic Colorectal Cancer. Accepted to Clinical Colorectal Cancer. 2020.

Winer A, Bains A. Autoimmune Panmyelosis with Myelofibrosis, Blood. 2019 Oct 10;134(15):1269.

Winer A, Ghalatlia P, Bubes N, Anari F, Varshavsky A, Kasireddy V, Liu Y, El-Diery, W. Dual checkpoint inhibition with ipilimumab plus nivolumab after progression on sequential PD-1/PDL-1 inhibitors pembrolizumab and atezolizumab in a patient with Lynch Syndrome, metastatic colon and localized urothelial cancer. The Oncologist. 2019 Aug 24;8:1-4.

El-Diery W, Winer A, Slifker M, Taylor S, Adamson B, Meropol N, Ross E. Disease control with FOLFIRI plus ziv-aflibercept (zFOLFIRI) beyond FOLFIRI plus bevacizumab: Case series in metastatic colorectal cancer (mCRC). Front Oncol. 2019 Mar 14;9:142.

Ghatalia P, Smith CH, Winer A, Gou J, Kiedrowski L, Slifker M, Saltzberg P, Bubes N, Anari F, Kasireddy V, Varshavsky A, Liu Y, Ross E, El-Deiry W. Clinical use of liquid biopsies (LB) to detect actionable driver mutations, guide treatment decisions and monitor disease burden during treatment of 33 metastatic colorectal cancer (mCRC) patients (pts) at a Fox Chase Cancer Center GI Oncology subspecialty clinic. Front Oncol. 2019 Jan 17;8:652.

Winer A, Bains A. Cryoglobulin-induced red blood cell morphologic changes. Blood. 2018 Jun 28;131(26):2994.

Winer A, Adams S, Mignatti P. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes. Mol Cancer Ther. 2018 Jun;17(6):1147-1155.

Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. J Thorac Dis. 2018 Feb;10(Suppl 3):S480-S489.

Winer A, Janosky M, Harrison B, Zhong J, Moussai D, Siyah P, Schatz-Siemers N, Zheng J, Adams S, Mignatti P. Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-Of-Principle Study. Mol Cancer Ther. 2016 Oct;15(10):2370-2377.

Janosky M, Sabado R, Cruz C, Vengco I, Hasan F, Winer A, Moy L, Adams S. MAGE-specific T cells detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy. Journal for ImmunoTherapy of Cancer, 2(32); 2014.

Background

Medical Education

New York University School of Medicine 2013

Residency

New York University Langone Medical Center
Training Specialty: Internal Medicine
07/01/2013 - 06/30/2017

Fellowships

Fox Chase Cancer Center
Training Specialty: Oncology and Hematology
7/1/2017 - 06/30/2020

Board Certification

Internal Medicine

Hospital Affliation

Inova Physician Referral Services

Please make note of the following information.

This referral service is sponsored by Inova. Only physicians with appropriate medical staff privileges at an Inova affiliated hospital may participate. There is no charge or fee to you or for the participating physician for our service. Physician participation is voluntary.

Physician referrals will be based on your referral needs and preferences of location, specialty, and rotation availability of the physician.

The physicians on our referral panel are independent practitioners or physician employees. The independent practitioners are not employees, agents or representatives of Inova and are solely responsible for their provision of medical care to you.